| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Submission example | NDA | — | Subscribe to access the data. | Peptides | Psychiatric Disorders | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Peptides | Psychiatric Disorders | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Peptides | Psychiatric Disorders |
Recent Updates
Recently added Catalysts
COMPASS Pathways Plc - American Depository Shares$13.31
+1.11 (+8.29%)
C 46Pipeline Score Overvalued Biotech · Clinical
Market Cap
1.59 B
EPS
-2.15
P/E Ratio
-
Value Trade
41.21 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
26.48 M
Operating CF
-47.94 M
Total Assets
531.74 M
Total Liabilities
205.05 M
Equity
326.69 M
D/E Ratio
12,345
14.11 %
Week
26.92 %
1 Month
43.5 %
3 Month
127.12 %
6 Month
-67.01 %
5 Year
-49.53 %
All Time
Cash Data
Cash Position
466.01 M
Monthly Burn
15.98 M
Runway
27.2 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
3.36 M
52 Week Range
2.25 - 12.24
% held by Insiders
4.58 %
% held by Institutions
66.01 %
Enterprise Value
1.18 B
Total Shares
134.92 M
Short %
7.9 %
Float Shares
128.74 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for COMPASS Pathways Plc - American Depository Shares
59Total events
5Upcoming
19Tier-1 (high impact)
2020 – 2028Coverage
Upcoming catalysts 2
TBD
T1NDA Submission
Subscribe to view catalyst details
TBD
T2Runway Guidance Update
Subscribe to view catalyst details
Event history 2
TBD
▲Full ResultsCOMP360FiledClinical Data
Subscribe to view catalyst details
TBD
●Oral PresentationPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
C46
Pipeline Score $686M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.4x
rNPV / MCap Top 68%
Micro Cap (rank 293 of 912)
Percentile RankCOMPASS Pathways Plc - American Depository Shares carries a moderate pipeline score (46/100), with $1.7B risk-adjusted pipeline value, led by Psilocybin in Major Depressive Disorder (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Psilocybin Small molecule | Major Depressive Disorder | Phase 3 | NCT05733546 | 54% | $1.5B | ACTIVE NOT_RECRUITING | 122 | SLOW | B (69) | Sep 1, 2025 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
COMP360 | treatment-resistant depression | Phase 3 | 2026-02-17 | p value: <0.001; clinically meaningful difference: -3.8 points Read More | Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression Read More | |
COMP360 | treatment-resistant depression | Phase 3 | 2026-02-17 | p value: <0.001; clinically meaningful difference: -3.8 points Read More | Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression Read More | |
COMP360 | treatment-resistant depression | Phase 3 | 2026-02-17 | p value: <0.001; clinically meaningful difference: -3.8 points Read More | Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CMPS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CMPS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CMPSCompass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
Compass Pathways has announced six-month data from its second Phase 3 trial. The results confirm a rapid and durable profile for their treatment. However, specific details regarding the outcomes and implications of the trial data were not provided in the announcement.
Read more →CMPSCompass Pathways Elects Kathleen Tregoning to Board of Directors
Compass Pathways has announced the election of Kathleen Tregoning to its Board of Directors. This decision reflects the company's commitment to enhancing its governance and leadership. Tregoning's experience is expected to contribute positively to the strategic direction of Compass Pathways.
Read more →CMPSCompass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026
Compass Pathways is scheduled to participate in the Jefferies Global Healthcare Conference on June 3, 2026. This event will provide a platform for the company to discuss its initiatives and developments in the healthcare sector. Further details regarding the presentation and topics to be covered have not been disclosed.
Read more →CMPSCompass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
Compass Pathways is set to participate in the RBC Capital Markets Global Healthcare Conference scheduled for May 19-20, 2026. This event will provide a platform for the company to discuss its developments and strategies in the healthcare sector. Further details regarding the presentation or topics to be covered have not been disclosed.
Read more →CMPS▲ +17%on this newsshared move
Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights
Compass Pathways has released its financial results for the first quarter of 2026, highlighting key business developments. The article provides insights into the company's performance and strategic initiatives during this period. However, specific details regarding financial figures or business highlights are not disclosed in the text provided.
Read more →CMPSCompass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026
Compass Pathways plc will announce its first quarter 2026 financial results on May 13, 2026. The announcement will be followed by a conference call at 8:00 am ET. The company is focused on developing innovative treatments for mental health, particularly through its investigational COMP360 treatment.
Read more →CMPSCompass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments
Compass Pathways has partnered with Osmind to prepare independent clinics for potential psychedelic treatments, specifically the investigational COMP360 psilocybin therapy. This collaboration aims to address operational and clinical needs, ensuring safe and effective delivery of treatments. Both companies seek to establish scalable care models for mental health conditions.
Read more →CMPS▲ +42%on this newsshared move
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026
Compass Pathways is set to participate in the Needham Virtual Psychedelics Forum scheduled for April 27, 2026. This event will likely focus on advancements and discussions in the psychedelics sector, although specific details about their participation are not provided in the article.
Read more →CMPSCompass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training
Compass Pathways has announced a new grant program aimed at creating training for providers following the approval of COMP360. This initiative is designed to support healthcare professionals in delivering effective treatment. The program highlights the company's commitment to enhancing accessibility and education surrounding their therapy.
Read more →CMPSCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 7, 2026
Compass Pathways plc announced the granting of equity awards to seven newly hired non-executive employees under its 2026 Inducement Plan. The awards include options to purchase shares and restricted share units, with vesting contingent on continued employment. The company is focused on innovative mental health treatments, particularly its investigational COMP360 psilocybin treatment, which has received Breakthrough Therapy designation from the FDA.
Read more →CMPSCompass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026
Compass Pathways is scheduled to participate in the Needham Virtual Healthcare Conference on April 14, 2026. This event will provide an opportunity for the company to engage with investors and discuss its ongoing projects and developments in the healthcare sector.
Read more →CMPSCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Pathways has announced new employee inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). This move is part of their strategy to enhance employee retention and attract talent. The specifics of the grants and their potential impact on the company are currently unclear.
Read more →CMPSCompass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights
Compass Pathways has released its financial results for the fourth quarter and full year of 2025. The report includes key business highlights, though specific details on performance metrics were not disclosed. The announcement reflects the company's ongoing activities and strategic direction in the biopharma sector.
Read more →CMPSCompass Pathways Announces Exercise of $200 Million in Outstanding Warrants
Compass Pathways plc has announced the exercise of 35,059,448 warrants, raising around $200 million. The funds will support ongoing Phase 3 trials for its COMP005 and COMP006 treatments, as well as its Phase 2b/3 trial of COMP360 for PTSD. The company expects these proceeds to cover operational expenses through 2028.
Read more →CMPSCompass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026
Compass Pathways plc will attend the TD Cowen 46th Annual Healthcare Conference in Boston from March 2-4, 2026. The company will participate in a fireside chat on March 3 at 10:30 AM ET. Compass is dedicated to advancing mental health treatments, particularly with its investigational COMP360 synthetic psilocybin, which has received FDA Breakthrough Therapy designation.
Read more →CMPSCompass Pathways announces pricing of $150 million public offering LONDON NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based
Compass Pathways plc announced the pricing of its public offering of 17,500,000 American Depositary Shares (ADSs) at $8.00 each, aiming to raise $150 million. The funds will primarily be allocated to ongoing Phase 3 trials for its investigational COMP360 treatment, which targets mental health conditions. Additionally, the offering includes an option for underwriters to purchase additional ADSs, and is expected to close around February 20, 2026, subject to customary closing conditions.
Read more →CMPS▲ +10.7%on this newsshared move
Compass Pathways Launches Proposed $150.0 Million Public Offering
Compass Pathways has announced a proposed public offering of $150 million of American Depositary Shares. The offering is aimed at accelerating patient access to innovative mental health treatments, particularly its investigational COMP360 psilocybin treatment. The company has granted underwriters a 30-day option to purchase additional shares. However, the completion of the offering is subject to market conditions.
Read more →CMPS▲ +31.3%on this news· ran to +45% by day 1shared move
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
Compass Pathways announced the successful achievement of the primary endpoint in its Phase 3 COMP006 trial for COMP360, a psilocybin treatment for treatment-resistant depression. The trial showed a significant reduction in depression symptoms compared to lower doses. The company plans to discuss a rolling submission with the FDA, aiming for an NDA submission in Q4. The findings highlight the treatment's rapid onset and sustained efficacy.
Read more →CMPS▲ +31.3%on this news· ran to +45% by day 1shared move
investorpresen 1 | Compass Pathways COMP360 Phase 3 Program Topline Results COMP005 & COMP006
Compass Pathways has reported positive topline results from its Phase 3 trials (COMP005 and COMP006) for the COMP360 psilocybin treatment aimed at treatment-resistant depression (TRD). The studies involved over 1,000 participants and demonstrated significant reductions in depression scores, with a quick onset of effects and sustained improvements for many patients. However, the results are marked by uncertainties, including the need for additional funding and potential regulatory hurdles that may affect future clinical and commercial development.
Read more →CMPS▲ +31.3%on this news· ran to +45% by day 1shared move
Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
Compass Pathways plc will announce new clinical data from two ongoing Phase 3 trials for its COMP360 treatment for treatment-resistant depression. The results will be released on February 17th at 6:30 am ET, followed by a webinar at 8:00 am ET. COMP360 has received Breakthrough Therapy designation from the FDA, highlighting its potential significance in mental health treatment.
Read more →CMPSCompass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors LONDON NEW YORK--(
Compass Pathways has appointed Dr. Jeffrey Jonas to its Board of Directors, effective immediately. Dr. Jonas brings over 30 years of leadership experience in pharmaceutical research and development, particularly in neuroscience. He replaces Thomas Lönngren, who will retire after six years of service. The company is focused on the advancement of its investigational product, COMP360, which aims to revolutionize treatments for mental health conditions. Dr. Jonas expressed excitement about contributing to Compass's mission to transform mental health care.
Read more →CMPS▼ -14.7%on this news
Compass Pathways Announces Pricing of Underwritten Offering London and New York
Compass Pathways has priced an underwritten offering of 24,014,728 American Depositary Shares (ADSs) and pre-funded warrants, generating expected gross proceeds of around $150 million. The funds will support ongoing Phase 3 trials for treatment-resistant depression and PTSD, with key data expected in 2025. The offering is set to close on January 13, 2025, pending customary closing conditions, and has attracted participation from notable institutional investors.
Read more →CMPS▼ -12.4%on this news
Document Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors David Norton Assumes Role of Interim Board Chair while the Company Runs a Globa
Compass Pathways announced that Board Chair and co-founder George Goldsmith and fellow co-founder Ekaterina Malievskaia are stepping down from the board of directors, effective March 29, 2024. David Norton will assume the role of interim chair while the company seeks a new board leader. Their departure comes as the company prepares for a potential commercial launch of its psilocybin treatment for mental health challenges. The outgoing co-founders leave behind a legacy of significant achievements, including key partnerships and clinical advancements in treatment-resistant depression.
Read more →CMPS▲ +7.9%on this news· ran to +39% by day 3
These risks, uncertainties, and other factors include, among others our plans to transition to a new chief financial officer may be unsuccessful clinical development is lengthy and outcomes are uncertain, and therefore o
Compass Pathways PLC announced the appointment of Teri Loxam as Chief Financial Officer, effective March 2024, to lead financial strategy amidst its ongoing clinical programs for mental health treatments. Loxam comes with extensive experience from her previous roles in various biotech companies and is expected to strengthen the company's financial position. The company continues to progress with its phase 3 clinical program for its COMP360 psilocybin treatment for treatment-resistant depression. However, the announcement included forward-looking statements that highlight potential risks related to clinical development and financial stability.
Read more →CMPSfuture developments or otherwise. These forward-looking statements are based on COMPASS's current expectations and speak only as of the date hereof. Enquiries Media Amy Lawrence, media compasspathways.com, +44 7813 777 9
COMPASS Pathways has announced the departure of CFO Mike Falvey, effective November 3, 2023. Mary-Rose Hughes, Vice President of Finance, will take on the interim CFO role while a search for a permanent replacement begins. The company expressed gratitude for Falvey's contributions, particularly in completing a recent private placement that extended the company's cash runway. COMPASS continues to advance its clinical program for COMP360, a psilocybin therapy designed for treatment-resistant depression.
Read more →CMPSThese risks, uncertainties, and other factors include, among others market risks and other market conditions clinical development is lengthy and expensive process with uncertain outcomes, and therefore our clinical trial
COMPASS Pathways plc has appointed Daphne Karydas as a member of its Board of Directors, effective September 18, 2023. Karydas, who has a solid background in biopharmaceutical finance, will contribute to the company's advancing programs, particularly the COMP360 psilocybin therapy targeting treatment-resistant depression. The appointment coincides with COMPASS's ongoing phase 3 clinical trials and acknowledges the recent successful fundraising that supports its initiatives in mental health innovation. However, the company also faces significant risks and uncertainties in clinical development and funding.
Read more →CMPS▲ +18.5%on this news
COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors Transaction led by healthcare specialist investors, TCGX and Aisling Capital $125 million financing upfront
COMPASS Pathways announced a private placement financing of up to $285 million, led by healthcare investors TCGX and Aisling Capital. This includes $125 million in upfront financing and potentially an additional $160 million depending on the exercise of warrants. The proceeds will support COMPASS's phase 3 clinical program for treatment-resistant depression and other mental health initiatives. The financing aims to elevate their psilocybin therapy developments, with a firm focus on meeting urgent patient needs in mental health care.
Read more →CMPSDocument COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital London, UK
COMPASS Pathways has successfully secured a term loan facility with Hercules Capital for up to $50 million to further its clinical programs. The initial drawdown of $30 million occurred on June 30, 2023, with additional funds available based on performance milestones. The financing is intended to support the company's phase 3 program targeting treatment-resistant depression, with critical data expected by summer 2024. This partnership strengthens COMPASS's financial position and extends its operational runway.
Read more →CMPSThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology su
COMPASS Pathways announced that Co-founder and Chief Innovation Officer, Dr. Ekaterina Malievskaia, will step down from her executive role effective June 16, 2023. Despite this transition, she will remain on the company's Board of Directors, ensuring continuity in leadership and strategy. Under her guidance, COMPASS has pursued innovative approaches in mental health care, particularly through its psilocybin therapy for treatment-resistant depression. The transition comes amid the company's progress towards a significant phase 3 clinical program for its groundbreaking therapy.
Read more →CMPScompassinvesto Transforming Mental Health Care
COMPASS Pathways plc is advancing its COMP360 psilocybin therapy for treatment-resistant depression (TRD), with plans for ongoing clinical trials targeting various mental health conditions. The company is preparing for phase 3 trials, which could support regulatory submissions. Despite its promising approach to mental health care, the project faces risks related to regulatory pathways and dependencies on external partnerships for trial execution. The company emphasizes the innovative nature of its therapies and their potential impact on a considerable patient population in need.
Read more →CMPScompassinvesto Transforming Mental Health Care JANUARY 2023 2 | COMPASS Pathways plc 2023 Cautionary Note Regarding Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of
COMPASS Pathways has presented results from a clinical trial evaluating COMP360 psilocybin therapy for treatment-resistant depression (TRD). The trial demonstrates a statistically significant reduction in depression symptoms shortly after administration, with effects sustained over a 12-week period. The data suggests that COMP360 could serve as a viable monotherapy option, indicating its potential importance in addressing unmet mental health needs. The findings have been published in a reputable medical journal, highlighting the robustness of the research.
Read more →CMPSquarterly report on Form 10-Q and in other reports we have filed with the U.S. Securities and Exchange Commission ("SEC") , which are available on the SEC's website at www.sec.gov. Except as required by law, COMPASS disc
COMPASS Pathways Appoints Kabir Nath as Chief Executive Officer Kabir Nath will build upon COMPASS' success and lead the development of novel models of care to accelerate patient access to evidence-based innovation in mental health care George Goldsmith remains COMPASS' Chairma
Read more →CMPS▼ -16.4%on this news
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression Largest randomised, controlled, double-blind psiloc
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression Largest randomised, controlled, double-blind psilocybin therapy study ever completed shows rapid and sustain
Read more →CMPSCOMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder London, UK - 3 November 2021 COMPASS Pathways plc (Nasdaq CMPS) ("COMPASS"), a mental health care company dedicat
COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder London, UK - 3 November 2021 COMPASS Pathways plc (Nasdaq CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innov
Read more →CMPSOpen-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups Investigator-initiated study shows remission in major de
Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups Investigator-initiated study shows remission in major depression symptoms for 50% of participants London, UK - 20
Read more →CMPS▲ +6.8%on this news· ran to +23% by day 3shared move
COMPASS Pathways is granted new US patent for crystalline psilocybin London, UK - 19 October 2021 COMPASS Pathways plc (Nasdaq CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to e
COMPASS Pathways is granted new US patent for crystalline psilocybin London, UK - 19 October 2021 COMPASS Pathways plc (Nasdaq CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today
Read more →CMPSDocument New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder Study concludes that psilocybin fin
New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder Study concludes that psilocybin findings should be explored further in larger studies London, UK - 1
Read more →CMPSDocument COMPASS Pathways granted two US patents London, UK - 23 March 2021 COMPASS Pathways plc (Nasdaq CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovati
COMPASS Pathways granted two US patents London, UK - 23 March 2021 COMPASS Pathways plc (Nasdaq CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted two n
Read more →CMPSDocument COMPASS Pathways plc announces financial results and business highlights for fourth quarter and year-end 2020 Highlights include continued progress with phase IIb psilocybin therapy clinical trial, launch of fir
COMPASS Pathways plc announces financial results and business highlights for fourth quarter and year-end 2020 Highlights include continued progress with phase IIb psilocybin therapy clinical trial, launch of first Centre of Excellence, and expansion of Discovery Center Phase
Read more →CMPSCOMPASS Pathways 2021 Transforming mental health care COMPASS Pathways plc February 2021 COMPASS Pathways 2021 Disclaimer This presentation has been prepared by COMPASS Pathways plc ("we", "us", "our", "COMPASS", "COMPAS
COMPASS Pathways 2021 Transforming mental health care COMPASS Pathways plc February 2021 COMPASS Pathways 2021 Disclaimer This presentation has been prepared by COMPASS Pathways plc ("we", "us", "our", "COMPASS", "COMPASS Pathways", or the "Company") and contains "forward-lookin
Read more →Competitive Position
How CMPS ranks across every disease it competes inCompetitive Position is a premium feature
See how CMPS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial